StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform- Financing Will Enable Stride to Move Multiple Programs Towards the Clinic - DURHAM, N. Car., June 13, 2018-- StrideBio, Inc, a US-based company developing novel AAV vectors for in vivo gene therapies announced today that it had closed an oversubscribed Series A Financing Round of $15.7 million. The financing was led by Hatteras Venture Partners. Co-investors include Takeda Ventures, Inc., UCB Ventures, and Alexandria Venture Investments, LLC.